Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction.
Duphaston
Dydrogesterone
In-vitro fertilization
Luteal phase support
Pharmacological profile
Progesterone
Journal
Reproductive biomedicine online
ISSN: 1472-6491
Titre abrégé: Reprod Biomed Online
Pays: Netherlands
ID NLM: 101122473
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
06
06
2018
revised:
15
08
2018
accepted:
07
11
2018
pubmed:
1
1
2019
medline:
31
3
2020
entrez:
1
1
2019
Statut:
ppublish
Résumé
The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.
Identifiants
pubmed: 30595525
pii: S1472-6483(18)30602-3
doi: 10.1016/j.rbmo.2018.11.017
pii:
doi:
Substances chimiques
Progestins
0
Dydrogesterone
90I02KLE8K
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-259Informations de copyright
Copyright © 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.